Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)

David R. Spigel; Craig H. Reynolds; David Waterhouse; Edward B. Garon; Jason C. Chandler; Sunil Babu; Paul J. Thurmes; Alexander I. Spira; Robert M. Jotte; Jin Zhu; Wen Lin; George R. Blumenschein

doi:10.1016/j.jtho.2018.02.022

Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)

著者: David R. Spigel, Craig H. Reynolds, David Waterhouse, Edward B. Garon, Jason C. Chandler, Sunil Babu, Paul J. Thurmes, Alexander I. Spira, Robert M. Jotte, Jin Zhu, Wen Lin, George R. Blumenschein - Journal of Thoracic Oncology 2018 被引用: 227

Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370) | Litlas